Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Bertamini

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Blood|October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasoneLuca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
Eclinicalmedicine|July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trialElena Zamagni, Stefania Oliva, Francesca Gay, et al.
Blood|November 21, 2024
Serum free light chains in a racially diverse population including African Americans and populations from South AfricaLuca Bertamini, Jean-Baptiste Alberge, David J Lee, et al.
Elife|May 4, 2021
Whole-genome sequencing analysis of semi-supercentenariansPaolo Garagnani, Julien Marquis, Massimo Delledonne, et al.
Nature Genetics|May 21, 2025
Genomic landscape of multiple myeloma and its precursor conditionsJean-Baptiste Alberge, Ankit K Dutta, Andrea Poletti, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Blood|October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasoneLuca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
Eclinicalmedicine|July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trialElena Zamagni, Stefania Oliva, Francesca Gay, et al.
Blood|November 21, 2024
Serum free light chains in a racially diverse population including African Americans and populations from South AfricaLuca Bertamini, Jean-Baptiste Alberge, David J Lee, et al.
Elife|May 4, 2021
Whole-genome sequencing analysis of semi-supercentenariansPaolo Garagnani, Julien Marquis, Massimo Delledonne, et al.
Nature Genetics|May 21, 2025
Genomic landscape of multiple myeloma and its precursor conditionsJean-Baptiste Alberge, Ankit K Dutta, Andrea Poletti, et al.
Pageof 3